Search

Harvey R Kaslow

from Pasadena, CA
Age ~75
Get Report
Also known as:
Harvey R Mcdonough, Harvey Mc Donough
Phone and address:
1340 Marianna Rd, Pasadena, CA 91105
(626) 644-1341
Related to:
Arthur L KaslowHolly F Harmon, 74Sophie Kaslow, 29Sarah R Kaslow, 37Alicia Ann Mcdonough, 74David C Kaslow, 66Kathleen A KaslowZoe H Kaslow, 32Abraham M Kaslow, 37Dorothy F Kaslow, 40
Connected to:
Jason S Kaslow, 37Susan M Kaslowe, 85Alex Kaslowitz, 37Justin A Kasmaker, 34Andrew T Kasman, 66Rahil M Kasmani, 52Zahir M Kasmani, 49Scott A Kasmann, 50Charles D Kasmar, 67Rocco J Kasmark, 32

Harvey Kaslow Phones & Addresses

  • 1340 Marianna Rd, Pasadena, CA 91105 (626) 644-1341
  • Glendale, CA
  • Los Angeles, CA
  • San Francisco, CA
  • 1340 Marianna Rd, Pasadena, CA 91105

Publications

Us Patents

Compositions Exhibiting Adp-Ribosyltransferase Activity And Methods For The Preparation And Use Thereof

View page
US Patent:
6514499, Feb 4, 2003
Filed:
Feb 22, 2000
Appl. No.:
09/510664
Inventors:
Harvey R. Kaslow - Los Angeles CA, 90039
International Classification:
A61K 3512
US Classification:
4241841, 4241901, 42419711, 4242361, 4242401, 4242771, 4242781, 424 941, 424 945, 514 2, 530350
Abstract:
Compositions characterized by ADP-ribosyltransferase activity are useful in promoting prophylactic and/or therapeutic responses as are promoted by, e. g. , pertussis toxin but directed against another target antigen (e. g. , a cancer-related antigen) in a mammalian patient.

Compositions Exhibiting Adp-Ribosyltransferase Activity And Methods For The Preparation And Use Thereof

View page
US Patent:
7341733, Mar 11, 2008
Filed:
Dec 6, 2002
Appl. No.:
10/314192
Inventors:
Harvey R. Kaslow - Los Angeles CA, US
International Classification:
A61K 45/00
US Classification:
4242781, 4242822
Abstract:
Compositions characterized by ADP-ribosyltransferase activity are useful in promoting prophylactic and/or therapeutic responses as are promoted by, e. g. , pertussis toxin but directed against another target antigen (e. g. , a cancer-related antigen) in a mammalian patient.

Compositions Exhibiting Adp-Ribosyltransferase Activity And Methods For The Preparation And Use Thereof

View page
US Patent:
60569603, May 2, 2000
Filed:
Jun 7, 1995
Appl. No.:
8/482758
Inventors:
Harvey R. Kaslow - Los Angeles CA
International Classification:
A61K 3512
A61K 3566
A61K 3910
US Classification:
4241841
Abstract:
Compositions characterized by ADP-ribosyltransferase activity are useful in promoting prophylactic and/or therapeutic responses as are promoted by, e. g. , pertussis toxin but directed against another target antigen (e. g. , a cancer-related antigen) in a mammalian patient.

Mutagenized Dna Molecules Encoding Modified Subunit A Of Cholera-Toxin

View page
US Patent:
58742875, Feb 23, 1999
Filed:
May 5, 1995
Appl. No.:
8/435605
Inventors:
W. Neal Burnette - Thousand Oaks CA
Harvey R. Kaslow - Los Angeles CA
Assignee:
Amgen Inc. - Thousand Oaks CA
International Classification:
C12N 100
C12N 510
C12N 121
C12N 1554
US Classification:
4352523
Abstract:
The development of subunits and subunit analogs of the cholera exotoxin by recombinant DNA techniques provides vaccine products that can retain their biological activity and immunogenicity, and can confer protection against disease challenge. Genetically-engineered modifications of the subunits result in products that retain immunogenicity, yet are reduced in, or are essentially free of, enzymatic activity associated with toxin reactogenicity.

Selective Modification Of The Catalytic Subunit Of Pertussis Toxin

View page
US Patent:
50323989, Jul 16, 1991
Filed:
Aug 1, 1986
Appl. No.:
6/893080
Inventors:
Harvey R. Kaslow - Los Angeles CA
International Classification:
A61K 3910
C07K 1504
US Classification:
424 92
Abstract:
A modified pertussis toxin suitable as a pertussis vaccine having an essentially unmodified B-oligomer and a catalytic subunit which is inactivated by treatment with polyphosphate compounds, sulfhydryl reductants and mild detergents followed by modification of the activated --SH groups to inhibit ADP-ribosylating activity.

Composition With Modified Pertussis Toxin

View page
US Patent:
51659271, Nov 24, 1992
Filed:
Apr 9, 1991
Appl. No.:
7/682773
Inventors:
Harvey R. Kaslow - Los Angeles CA
Assignee:
University of Southern California - Los Angeles CA
International Classification:
A61K 3910
US Classification:
424 92
Abstract:
A modified pertussis toxin suitable as a pertussis vaccine having an essentially unmodified B-oligomer and a catalytic subunit which is inactivated by treatment with polyphosphate compounds, sulfhydryl reductants and mild detergents followed by modification of the activated --SH groups to inhibit ADP-ribosylating activity.

Modified Cholera Toxin Based On Mutagenized Subunit A

View page
US Patent:
57702039, Jun 23, 1998
Filed:
May 24, 1995
Appl. No.:
8/449045
Inventors:
W. Neal Burnette - Thousand Oaks CA
Harvey R. Kaslow - Los Angeles CA
Assignee:
Amgen Inc. - Thousand Oaks CA
University of Southern California - Los Angeles CA
International Classification:
A61K 39106
C12N 910
C07K 1428
US Classification:
4241901
Abstract:
The development of subunits and subunit analogs of the cholera exotoxin by recombinant DNA techniques provides vaccine products that can retain their biological activity and immunogenicity, and can confer protection against disease challenge. Genetically-engineered modifications of the subunits result in products that retain immunogenicity, yet are reduced in, or are essentially free of, enzymatic activity associated with toxin reactogenicity.

Secretory Tnt Car Cell Immunotherapy

View page
US Patent:
20180291089, Oct 11, 2018
Filed:
Apr 29, 2016
Appl. No.:
15/570747
Inventors:
- Los Angeles CA, US
Harvey Kaslow - Los Angeles CA, US
Peisheng Hu - Covina CA, US
International Classification:
C07K 16/18
C07K 14/705
C07K 14/725
C07K 14/47
A61K 45/06
A61K 38/17
A61K 39/395
A61K 38/20
A61K 38/19
C07K 14/54
C07K 14/535
C07K 14/55
C07K 14/52
Abstract:
CAR cells targeting tumor necrosis therapy relevant antigens are described as a new method of cancer treatment. It is proposed that TNT CAR cells are safe and effective in patients and can be used to treat human tumors and cancer.
Control profile
Harvey R Kaslow from Pasadena, CA, age ~75 Get Report